Search the Newsreel

Zevra Therapeutics (NASDAQ:ZVRA) Announces Quarterly Earnings Results

Q2 2026 Zevra Therapeutics Inc Earnings Call Transcript

Key Points Interested in Zevra Therapeutics, Inc.? Here are five stocks we like better. Revenue grew strongly: Zevra's Q2 2026 net revenue rose 53% year over year to $39.7 million, led by MIPLYFFA U.S. revenue of $30.2 million. Adjusted net income was $15.2 million, …

Zevra Therapeutics, Inc. (NASDAQ: ZVRA) posts Q2 profit, repays debt

Zevra executives set to present at Boston growth conference

Zevra Therapeutics announced that its executive leadership team will present at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA, on Tuesday, August 11, 2026, at 11:00 a.m. ET. Management will also be available for one-on-one meetings, and a live webcast of the …

Vraj Iron & Steel Ltd Valuation Shifts to Fair Amidst Sector Challenges

Zevra Therapeutics (ZVRA) Securities Investigation Notice - Levi & Korsinsky

Levi & Korsinsky has initiated a securities investigation into Zevra Therapeutics (ZVRA) following a significant 24% stock drop on July 24, 2026. This decline occurred after the European Medicines Agency's CHMP issued a negative opinion on the Marketing Authorization Application for arimoclomol, branded Meplyffa. …

Zevra Therapeutics Announces Publication of 4-Year Real-World Data on MIPLYFFA in Niemann-Pick Disease Type C

Zevra Therapeutics has announced the publication of 4-year real-world data on its drug MIPLYFFA (arimoclomol) for Niemann-Pick disease type C (NPC) in Molecular Genetics and Metabolism. The study, involving 109 participants, demonstrated long-term safety and effectiveness, showing stable disease severity over time, particularly for …

Zevra's First Published Adult Niemann-Pick Data Includes Up to 4 Years

Zevra Therapeutics announced the publication of four-year real-world data from its U.S. Early Access Program for MIPLYFFA (arimoclomol) in Niemann-Pick disease type C (NPC). The study, detailed in Molecular Genetics and Metabolism, followed 109 participants, including 53 adults, and showed that disease severity remained …

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zevra Therapeutics, Inc. (ZVRA) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Zevra Therapeutics, Inc. (ZVRA) following a negative opinion from the European Medicines Agency regarding its drug, arimoclomol, which caused a sharp drop in Zevra's stock price. The firm is encouraging investors who purchased Zevra …

Zevra Therapeutics, Inc. - Common Stock (NQ: ZVRA)

This article provides recent news headlines related to Zevra Therapeutics, Inc. (ZVRA), including multiple investor alerts about investigations into the company. It also mentions a presentation of new data and a resubmission of a New Drug Application to the FDA. The stock's current delayed …

Do Weaker Recoveries Challenge Elevra Lithium’s Cost Profile And Earnings Quality Story (ASX:ELV)?

Bronstein, Gewirtz & Grossman, LLC Encourages Zevra Therapeutics, Inc. (ZVRA) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of investors who purchased Zevra Therapeutics, Inc. (ZVRA) securities. This investigation follows a negative opinion from the European Medicines Agency's CHMP regarding the Marketing Authorization Application for arimoclomol, which caused a sharp drop …

Zevra Therapeutics Market Sentiment

This article provides an overview of Zevra Therapeutics (ZVRA) market sentiment, including analyst consensus, short interest, and recent insider activity. It highlights that 15 analysts have a "Buy" consensus with an average price target of $23, and mentions several recent insider acquisitions of stock …

Vanguard Capital Management (ZVRA) discloses 3.0M-share Zevra Therapeutics position on 13G

Vanguard Capital Management has filed a Schedule 13G, disclosing a passive ownership stake of 3,024,980 shares in Zevra Therapeutics Inc (ZVRA), representing 5.11% of the outstanding common stock. Vanguard holds sole voting power over 386,070 shares and sole dispositive power over all 3,024,980 shares, …

Saba Capital Management L.P. Invests $916,000 in Vera Bradley, Inc. $VRA

Saba Capital Management L.P. acquired 290,000 shares of Vera Bradley (NASDAQ:VRA) worth approximately $916,000, establishing a 1.02% stake in the company. Other hedge funds also made significant moves, with institutional investors collectively owning nearly 60% of the stock. Despite a consensus "Reduce" rating from …

Elevra Lithium (ASX:ELV) Following Quarterly Production Results, Is The Undervalued Case Still Intact?

Zevra Therapeutics Inc (ZVRA) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Zevra Therapeutics Inc (ZVRA), highlighting its current valuation score and P/E ratio within the Pharmaceuticals industry. It notes that the company's valuation score is 7.58, ranking 120 out of 155, and its P/E ratio is 4.57, which …

Zevra Therapeutics (ZVRA) Stock Forum and Discussion

This article provides a platform for discussion and a forum for investors interested in Zevra Therapeutics (ZVRA) stock. It serves as a central point for sharing insights, news, and analysis related to the company's performance and future outlook.

Vera Bradley Inc (VRA) Institutional Confidence

Vera Bradley Inc (VRA) has an institutional shareholding score of 3.00, placing it 29th out of 36 in the Textiles & Apparel industry. The institutional shareholding proportion is 37.02%, marking an 11.61% quarter-over-quarter decrease. The largest institutional shareholder is Bill Nygren | OAKMX, holding …

Levi & Korsinsky Announces Investigation of Securities Claims Against Zevra Therapeutics, Inc. (ZVRA)

Levi & Korsinsky has initiated an investigation into Zevra Therapeutics, Inc. (ZVRA) following a significant 24% pre-market stock drop on July 24, 2026. This decline occurred after the European Medicines Agency's CHMP issued a negative opinion on the Marketing Authorization Application for arimoclomol, Zevra's …

Vera Bradley Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance | TradingKey

This article provides a detailed profile of Vera Bradley Inc (VRA), a designer of women's handbags, luggage, and accessories, outlining its business segments, financial data, and market performance. It includes key company information such as its IPO date, address, and executive team, along with …

Zevra Therapeutics (ZVRA) Expected to Announce Quarterly Earnings on Wednesday

Bronstein, Gewirtz & Grossman, LLC Is Investigating Zevra Therapeutics, Inc. (ZVRA) And Encourages Stockholders to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zevra Therapeutics, Inc. (ZVRA) after the company received a negative opinion from the European Medicines Agency regarding its drug arimoclomol, leading to a sharp drop in stock price. The firm …

ZVRA SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Zevra Therapeutics

SueWallSt, powered by Levi & Korsinsky LLP, is investigating potential securities claims against Zevra Therapeutics (NASDAQ: ZVRA) following a significant stock drop on July 24, 2026. The decline occurred after the European Medicines Agency's CHMP issued a negative opinion on Zevra's drug arimoclomol for …

ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (SBS) has launched an investigation into Zevra Therapeutics, Inc. (NASDAQ: ZVRA) for potential securities law violations after Zevra received a negative opinion from the European Medicines Agency regarding its drug arimoclomol (Meplyffa), causing its shares to fall significantly. SBS …

Zevra Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Zevra Therapeutics (ZVRA)

Levi & Korsinsky, LLP has launched an investigation into Zevra Therapeutics (ZVRA) after its shares dropped approximately 24% following a negative opinion from European regulators on arimoclomol, their lead product for Niemann-Pick disease type C. The investigation aims to determine if investors who suffered …

Vera Bradley Inc (VRA) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Vera Bradley Inc (VRA), listing major individual and institutional holders and their proportions. It also categorizes shareholders by type and tracks institutional shareholding and activity over recent quarters. The data indicates shifts in ownership, including increases and …

Zevra Europe Entry Plans For Neimann-Pick Drug Put On Hold

Zevra Therapeutics has put its plans for entering the European market with its Niemann-Pick disease drug on hold. The article, authored by Kevin Grogan, provides this key update regarding the company's strategy for its rare disease treatment.

H.C. Wainwright reiterates Zevra stock rating on EU setback

H.C. Wainwright has reiterated its Buy rating and $26.00 price target for Zevra Therapeutics (NASDAQ:ZVRA) despite a regulatory setback in Europe for MIPLYFFA. The firm believes the issues are related to statistical analysis rather than new concerns, and Zevra plans to seek re-examination of …

Zevra Therapeutics, Inc. Revenue Breakdown – NASDAQ:ZVRA

Vera Bradley Inc (VRA) Income Statement

This article provides the quarterly and annual income statements for Vera Bradley Inc (VRA), offering detailed financial data such as total revenue, operating expenses, and net income. It also includes key financial metrics like basic and diluted earnings per share, alongside an FAQ section …

Vera Bradley, Inc. Revenue Breakdown – NASDAQ:VRA

Vera Bradley, Inc. (NASDAQ:VRA) generated $269.65 million in revenue last year, with its Vera Bradley Direct segment being the top performer, contributing $227.79 million. The vast majority of its revenue, $269.65 million, came from the United States. This represents a decrease from the previous …

VRA|Vera Bradley Inc|Price:3.690|Chg%:+0.010

Vera Bradley Inc. (VRA) is trading at $3.69, up 0.27%, with positive year-to-date and 1-year performance. The company's fundamentals are robust, but its stock is currently in a sideways trading pattern, rated as "Hold" by analysts with a target price of $5.50. Institutional ownership …

Zevra To Appeal EMA's Negative Opinion On Arimoclomol For Niemann-Pick Disease Type C

Zevra Therapeutics announced that the European Medicines Agency (EMA) has issued a negative opinion on its Marketing Authorization Application for Arimoclomol, a treatment for Niemann-Pick disease type C. The company plans to appeal this decision, asserting confidence in the drug's potential based on existing …

Zevra Therapeutics Down Over 24%, on Pace for Largest Percent Decrease Since March 2021 -- Data Talk

Zevra Therapeutics is experiencing a significant stock decline, down over 24%. This places the company on track for its largest single-day percentage decrease since March 2021, according to Data Talk. The article content is empty, so no further details are available regarding the cause …

Vera Bradley Inc (VRA) Valuation: PE, PB & Fair Value Analysis

The article provides a valuation analysis of Vera Bradley Inc (VRA), noting its current valuation score of 7.85 and ranking within the Textiles & Apparel industry. It highlights the company's P/E ratio of -2.15, comparing it to recent highs and lows. The analysis also …